These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8598120)

  • 41. [Tumor markers MCA and CA-125 in the diagnosis and monitoring of breast cancer].
    Shakhtarin VV; Izotova IA; Parshkov EM; Chekin SIu; Simakova GM
    Vopr Onkol; 1992; 38(4):433-9. PubMed ID: 1300737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon.
    Bon GG; Verheijen RH; Zuetenhorst JM; van Kamp GJ; Verstraeten AA; Kenemans P
    Gynecol Obstet Invest; 1996; 42(1):58-62. PubMed ID: 8840180
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Determination of the tumor marker CA 72-4 in gastric carcinoma].
    Martín-Pérez E; Fernández-Arjona M; Baza B; Villanueva C; Larrañaga E; Serrano PA; Clerigué A
    Rev Esp Enferm Dig; 1993 Feb; 83(2):92-6. PubMed ID: 8471361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined use of urinary UGP and serum CA 125 in the diagnosis of gynecological cancers.
    Plebani M; Navaglia F; Basso D; De Paoli M; Nicoletto MO; Maraglino E; Torre GC
    Anticancer Res; 1996; 16(6B):3833-8. PubMed ID: 9042266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Technical evaluation of three second generation CA 125 assays.
    Bonfrer JM; Baan AW; Jansen E; Lentfer D; Kenemans P
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):201-7. PubMed ID: 8031969
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening for ovarian cancer. Multiple markers may outperform CA 125 alone.
    Bast R; Woolas R
    BMJ; 1993 Jun; 306(6893):1684-5. PubMed ID: 8324445
    [No Abstract]   [Full Text] [Related]  

  • 47. CA 242--a step ahead.
    Shahi SK; Ranga S; Bhullar C
    Indian J Pathol Microbiol; 2002 Apr; 45(2):145-6. PubMed ID: 12696727
    [No Abstract]   [Full Text] [Related]  

  • 48. Ca-125 levels in the conditioned media of the gynecological tumor cell lines.
    Ishiwata I; Ishiwata C
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jan; 37(1):147-8. PubMed ID: 3855943
    [No Abstract]   [Full Text] [Related]  

  • 49. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
    Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rapid measurement of corticotropin (ACTH) with a modified immunochemiluminescent assay.
    Raff H; Shaker JL; Nelson DK; Findling JW
    Clin Chem; 1994 Jul; 40(7 Pt 1):1344. PubMed ID: 8013111
    [No Abstract]   [Full Text] [Related]  

  • 51. Tumor markers CA 19-9 and CA 195 are also useful as markers for cystic fibrosis.
    Wu JT; Olson J; Walker K
    J Clin Lab Anal; 1992; 6(3):151-61. PubMed ID: 1506983
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sources of variability in normal CA 125 levels.
    Westhoff C; Levin B; Ladd G; O'Connor J
    Cancer Epidemiol Biomarkers Prev; 1992; 1(5):357-9. PubMed ID: 1305467
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Usefulness of determining tumor markers CEA, CA125 and CA72-4 in blood serum of patients with ovarian carcinoma].
    Kokocińska D; Worwag J; Tomala J; Dzieciuchowicz L; Nowak S; Kuśmierski S
    Ginekol Pol; 1994 Sep; 65(9):495-501. PubMed ID: 7721162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum levels of tumour associated glycoprotein (TAG 72) in patients with gynaecological malignancies.
    Scambia G; Benedetti Panici P; Perrone L; Sonsini C; Giannelli S; Gallo A; Natali PG; Mancuso S
    Br J Cancer; 1990 Jul; 62(1):147-51. PubMed ID: 2167724
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical use of gynaecologic tumour markers.
    Halila H; Alfthan H; Stenman UH
    Ann Chir Gynaecol; 1989; 78(1):65-70. PubMed ID: 2547331
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125.
    van Ingen HE; Chan DW; Hubl W; Miyachi H; Molina R; Pitzel L; Ruibal A; Rymer JC; Domke I
    Clin Chem; 1998 Dec; 44(12):2530-6. PubMed ID: 9836722
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multicenter evaluation of the Elecsys CA 125 II assay.
    Hubl W; Chan DW; Van Ingen HE; Miyachi H; Molina R; Filella X; Pitzel L; Ruibal A; Rymer JC; Bagnard G; Domke I
    Anticancer Res; 1999; 19(4A):2727-33. PubMed ID: 10470230
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Experience with CA 15.3 as a tumor marker in breast cancer.
    Barros AC; Fry W; Nazario AC; Santos MO; Sato MK
    Eur J Surg Oncol; 1994 Apr; 20(2):130-3. PubMed ID: 8181577
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sialyl Lewis-Xi antigen in patients with gynecologic tumors.
    Inoue M; Shimizu C; Sasagawa T; Shimizu H; Saito J; Tanizawa O
    Obstet Gynecol; 1989 Jan; 73(1):79-83. PubMed ID: 2909045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [CEA, CA 19.9 and CA 195 in patients with colorectal carcinoma. ROC analysis].
    Vallejo J; Torres-Avisbal M; Contreras P; Rodríguez-Liñán M; Rebollo A; González F; Benítez A; Infante J; Mateo A
    Rev Esp Med Nucl; 1999 Aug; 18(4):281-6. PubMed ID: 10481111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.